• Commencing 8 new projects after the third quarter of 2023. Those projects were announced during previous periods, especially in the general maintenance, catering and contracting divisions, which led to an increase in operating revenues.

• An increase in sales of the medical devices and equipment division by 45% compared to the same quarter of the previous year.

Several projects were awarded to the company (which were announced during previous periods), and most of these projects will start operation during the remainder of 2024 and the first half of 2025, which will positively impact the company’s results before the end of the current year 2024 and the following years.

• Commencing operation on 8 new projects after the third quarter of 2023

• An increase in sales of the medical devices and equipment division by 57% over the same period of the previous year.

2. Earnings per share from continuing operations also increased to 1.18 riyals per share during the current period, an increase of 7.3% over the same period of the previous year.

3. Earnings per share were adjusted for the similar period of the previous year after increasing the company’s capital, which was approved by the company’s extraordinary general assembly, which was held on September 3, 2023, where the extraordinary general assembly approved an increase in the company’s capital by 100 million Saudi riyals, with a corresponding increase in the number of issued ordinary shares. The company issued 10 million shares without nominal value.

This increase was achieved through capitalization of the company's retained earnings. Each shareholder was granted one bonus share for every two shares held. The company's capital after the increase amounts to 300 million Saudi riyals, divided into 30 million fully paid ordinary shares with equal voting rights.

4. On 25 August 2024, “Girgas Drug Store Trading Co.” (a subsidiary) signed a sale and assignment contract with “Nada Al Hayat Medical Holding Company” to sell all of the shares owned by Girgas in “Naqaa United Pharmaceutical Company”. The sale and transfer of ownership and control took place before 30 September 2024.

In compliance with International Financial Reporting Standard IFRS 5, all account related to the sold company “Naqaa” were excluded from all consolidated financial statements for the periods up to the date of disposal compared to similar periods of the previous year.

5. For the purpose of comparison with audited financial statements during previous periods, following statement shows the proforma interim condensed consolidated financial statements for the period ending 30 September 2024 (nine months), including discontinued operations.